DePuy Tracy, Howard Rick, Keegan Kevin, Wilson David, Kramer Joanne, Cook James L, Childers Martin K
From the Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri-Columbia, Columbia, Missouri, USA.
Am J Phys Med Rehabil. 2007 Oct;86(10):777-83. doi: 10.1097/PHM.0b013e3181157718.
To test the hypothesis that botulinum toxin type A (BoNT-A) can attenuate lameness associated with acute synovitis in an equine model.
Four horses 2-6 yrs of age with clinically normal carpi were studied for 15 days. Kinematic gait analysis and clinical measures of lameness were conducted before and after experimental interventions. Horses were randomly assigned to either placebo (saline) or treatment (BoNT-A) groups. On day 0 of the intervention, 50 units of BoNT-A or an equivalent volume of saline (0.09%) was given into the middle carpal joints. On day 14, acute synovitis was induced with intra-articular injection of recombinant equine interleukin-1 beta (IL-1 beta) 100 ng. Synovial fluid, clinical evaluation of lameness, and kinematic gait analysis were evaluated on day 15.
Synovitis was observed on histology and cytology in all horses after IL-1 beta, indicating acute suppurative inflammation. In the BoNT-A group, one horse developed lameness, whereas the other demonstrated no change in baseline gait evaluation. No adverse effects were observed in joints injected with BoNT-A or with saline alone.
Our findings support the idea that BoNT-A can attenuate lameness in an equine model of acute synovitis. Our findings further suggest that BoNT-A might be a potential new treatment for painful arthritis; this warrants further study.
验证A型肉毒杆菌毒素(BoNT-A)可减轻马急性滑膜炎所致跛行这一假说。
对4匹2至6岁腕关节临床正常的马进行为期15天的研究。在实验干预前后进行运动步态分析和跛行临床测量。马被随机分为安慰剂(生理盐水)组或治疗(BoNT-A)组。在干预第0天,向腕中关节注射50单位BoNT-A或等量生理盐水(0.09%)。在第14天,通过关节内注射100 ng重组马白细胞介素-1β(IL-1β)诱导急性滑膜炎。在第15天评估滑液、跛行临床评估和运动步态分析。
IL-1β注射后,所有马匹的组织学和细胞学检查均发现滑膜炎,表明为急性化脓性炎症。在BoNT-A组,一匹马出现跛行,而另一匹马在基线步态评估中无变化。在注射BoNT-A或仅注射生理盐水的关节中未观察到不良反应。
我们的研究结果支持BoNT-A可减轻马急性滑膜炎模型中跛行的观点。我们的研究结果还表明,BoNT-A可能是一种治疗疼痛性关节炎的潜在新疗法;这值得进一步研究。